Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
AssigneeAstraZeneca AB
InventorsPer Lindberg, Joan Pinas-Masso, Jordi Serra-Carreras, Jan Trofast
Life of this patent
Estimating the term…
Abstract
The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+,K+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.
Claims18
Use of an H+,K+-ATPase inhibitor in the manufacture of a medicament for the treatment of nasal polyps.
Use of an H+,K+-ATPase inhibitor in the manufacture of a medicament for the treatment of Widal's Syndrome.
Use of an H30,K+-ATPase inhibitor and a glucocorticoid in the manufacture of a pharmaceutical formulation intended for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome.
Use of an H30,K+-ATPase inhibitor and a glucocorticoid in the manufacture of a pharmaceutical formulation intended for simultaneous, separate or sequential administration in the treatment of asthma.
Use according to any one of the preceding claims wherein the H30, K+-ATPase inhibitor is a compound of formula 4
- wherein Het1 is 5
- wherein N in the benzimidazole moiety of Het2 means that one of the ring carbon atoms substituted by R6-R9 optionally may be exchanged for a nitrogen atom without any substituents;
- R1 and R3 each independently represent hydrogen, alkyl, or alkoxy on the condition that R1 and R3 do not simultaneously represent alkoxy;
- and R2 represents alkyl, alkoxy optionally substituted by fluorine, alkylthio or alkoxyalkoxy;
- or one of R1 and R3 is halogen and the other is hydrogen and R2 is 1-morpholino, 1-piperidino or dialkylamino;
- R4 and R5 are the same or different and selected from hydrogen and alkyl;
- R6-R9 are the same or different and selected from hydrogen, halogen, alkyl, alkoxy, haloalkoxy, alkylcarbonyl, and alkoxycarbonyl;
- R10 is hydrogen or R10 and R3 together complete a ring containing 6 to 8 carbon atoms;
- and
- R11 represents hydrogen, halogen or alkyl;
- wherein the compound of formula (1) is optionally in the form of a pharmaceutically acceptable alkaline salt or in its neutral form or is a single enantiomer or a racemic mixture thereof;
- wherein each alkyl or alkylenyl moiety has a branched or straight chain and has 1 to 6 carbon atoms.
A method for the treatment of nasal polyps which method comprises treating a subject suffering from the said condition with a pharmaceutical formulation comprising an H+,K+-ATPase inhibitor.
A method for the treatment of Widal's Syndrome which comprises treating a subject suffering from the syndrome with a pharmaceutical formulation comprising an H+,K+-ATPase inhibitor.
A method for the treatment of Widal's Syndrome which comprises simultaneously, separately or sequentially administration to a subject suffering from the syndrome with a pharmaceutical formulation comprising an H+,K+-ATPase inhibitor and a glucocorticoid.
A method for the treatment of asthma which comprises simultaneously, separately or sequentially administration to a subject suffering from the syndrome with a pharmaceutical formulation comprising an H30,K+-ATPase inhibitor and a glucocorticoid.
A pharmaceutical formulation for simultaneous, separate or sequential use in the treatment of Widal's Syndrome which formulation comprises an H+,K+-ATPase inhibitor and a glucocorticoid.
A pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of asthma which pharmaceutical formulation comprises an H30,K+-ATPase inhibitor and a glucocorticoid.
Dependencies are inferred from the claim text.